REMIT-iDegLira is a multicentre, open-label, randomized controlled trial in patients with recently-diagnosed type 2 diabetes (T2DM).

Participants will be randomized to two treatment groups:

(a) A 16-week period of lifestyle coaching support, metformin and a once-daily injection of IDegLira, and;

(b) Standard diabetes therapy, and followed for a total of 68 weeks (1 year and 4 months).

In all participants with HbA1C less than 7.3% at the 16-week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring.

Participants with HbA1C greater than or equal to 7.3% at this visit, or whose HbA1C is greater than or equal to 7.0% at or after the 28 week visit, will receive standard glycemic management.

Primary outcome:

Drug-free diabetes remission defined as a HbA1C less than 6.5% without use of glucose-lowering agents for at least 12 weeks.

Study Type

Interventional - Drug

Study Design

Multicentre, open-label RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2019 - 2023



Novo Nordisk

Back To Top